Comparative Pharmacology
Head-to-head clinical analysis: DANAZOL versus DELATESTRYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANAZOL versus DELATESTRYL.
DANAZOL vs DELATESTRYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Danazol is a synthetic androgen derived from ethisterone that suppresses pituitary-ovarian axis by inhibiting gonadotropin release, leading to decreased estrogen and progesterone levels. It also has weak androgenic and progestational activity.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
300-600 mg orally twice daily; maximum 800 mg/day
50 to 200 mg intramuscularly every 2 to 4 weeks.
None Documented
None Documented
Terminal elimination half-life is 4-4.5 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
Clinical Note
moderateDanazol + Tolbutamide
"The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Rosiglitazone
"The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Pioglitazone
"The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Saxagliptin
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
Primarily hepatic metabolism; approximately 60% excreted in feces, 30% in urine as metabolites.
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Category C
Category C
Androgen/Antigonadotropin
Androgen
"The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Danazol."